GlassScriptPhysician profile
Rosemarie Eason Mcfather
NPI 1316565179
$13,157.97
in general payments reported to CMS, 2019-2025
31 companies · $3,619 in 2025
The $3,619 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,004 · 2022: $2,214 · 2023: $2,214 · 2024: $3,106 · 2025: $3,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,589 · Education: $351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,588.50 |
| Education | $351.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,417.15 | 2021-2025 | |
| Janssen Biotech, INC. | $1,638.51 | 2021-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $1,533.29 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,291.76 | 2021-2025 | Relistor, Xifaxan, Trulance |
| Celgene Corporation | $861.19 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $732.75 | 2023-2025 | Ibsrela |
| Celltrion USA INC. | $458.15 | 2024-2025 | Zymfentra, Vegzelma |
| Regeneron Healthcare Solutions, INC. | $397.31 | 2022-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $332.92 | 2021-2023 | |
| Pfizer INC. | $322.28 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $314.23 | 2021-2025 | Linzess |
| Phathom Pharmaceuticals, INC. | $277.90 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $216.06 | 2021-2024 | Sucraid |
| Ferring Pharmaceuticals INC. | $200.07 | 2021-2025 | Rebyota |
| Lilly USA, LLC | $173.94 | 2024-2025 | Omvoh |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $158.51 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Ipsen Biopharmaceuticals, INC | $155.24 | 2025 | Bylvay, Iqirvo |
| E.R. Squibb & Sons, L.L.C. | $122.98 | 2022 | |
| Alnylam Pharmaceuticals INC. | $111.68 | 2021-2025 | Givlaari |
| Aimmune Therapeutics, INC. | $94.14 | 2024-2025 | Zenpep |
| Braintree Laboratories, INC. | $75.53 | 2021-2025 | Suflave, Sutab |
| Intercept Pharmaceuticals, INC. | $59.50 | 2021-2025 | |
| Evoke Pharma, INC. | $36.10 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $33.25 | 2021 | |
| Enterra Medical, INC. | $32.10 | 2023-2024 | |
| Blueprint Medicines Corporation | $23.96 | 2024 | Ayvakit |
| Daiichi Sankyo INC. | $20.91 | 2021 | |
| Sandoz INC. | $20.32 | 2025 | Hyrimoz |
| Fresenius Kabi USA, LLC | $19.46 | 2023 | Idacio |
| Gilead Sciences, INC. | $15.38 | 2021 | |
| Intra-Sana Laboratories | $11.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosemarie Mcfather listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.